<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02999009</url>
  </required_header>
  <id_info>
    <org_study_id>78</org_study_id>
    <nct_id>NCT02999009</nct_id>
  </id_info>
  <brief_title>Trident II Tritanium Acetabular Shell Outcomes Study</brief_title>
  <official_title>A Prospective, Post-market, Multi-center Study of the Trident II Tritanium Acetabular Shell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Orthopaedics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to review the performance and success rate of an FDA approved
      cementless hip replacement part called the Trident II Tritanium Acetabular Shell. The study
      will specifically look at the need to revise the hip replacement after 5 years. This will be
      compared to how much this happens in patients who have hip replacement with similar
      cementless acetabular shells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Anticipated">February 2029</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of Revision for the Trident II Tritanium Acetabular Shell</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Revision and Removal Rates for the Trident II Tritanium Acetabular Shell</measure>
    <time_frame>10 years</time_frame>
    <description>Survivorship percentage (one reported value) for both all-cause revision + removal will be indicated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Stability</measure>
    <time_frame>6 weeks, 3-6 months, 1, 2, 5, 7, 10 years</time_frame>
    <description>Numerous parameters will be reviewed by zone, including radiolucency and migration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <arm_group>
    <arm_group_label>Trident II Tritanium Acetabular Shell</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trident II Tritanium Acetabular Shell</intervention_name>
    <description>A hemispherical acetabular shell indicated for cementless application.</description>
    <arm_group_label>Trident II Tritanium Acetabular Shell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A. Patient has signed an Institutional Review Board (IRB) approved, study specific Informed
        Patient Consent Form.

        B. Patient is a male or non-pregnant female age 18-80 years of age at the time of study
        device implantation.

        C. Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease.

        D. Patient is a candidate for a primary cementless total hip replacement.

        E. Patient is willing and able to comply with postoperative scheduled clinical and
        radiographic evaluations.

        Exclusion Criteria:

        F. Patient has a Body Mass Index (BMI) â‰¥ 40.

        G. Patient is diagnosed with Inflammatory Arthritis.

        H. Patient has an active or suspected latent infection in or about the affected hip joint
        at time of study device implantation.

        I. Patient has a neuromuscular or neurosensory deficiency, which limits the ability to
        evaluate the safety and efficacy of the device.

        J. Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic
        disorder (e.g. Paget's Disease) leading to progressive bone deterioration.

        K. Patient is immunologically suppressed or receiving steroids in excess of normal
        physiological requirements (e.g. &gt; 30 days).

        L. Patient requires revision surgery of a previously implanted total hip replacement or hip
        fusion to the affected joint.

        M. Patient has had previous open surgery to the affected joint, not including arthroscopy.

        N. Patient requires implantation of a constrained liner.

        O. Patient has a known sensitivity to device materials.

        P. Patient is a prisoner.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alana Levine, MS</last_name>
    <phone>201-831-5492</phone>
    <email>alana.levine@stryker.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tucson Orthopaedic Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Phinizy</last_name>
      <phone>520-784-6141</phone>
      <email>aphinizy@tucsonortho.com</email>
    </contact>
    <investigator>
      <last_name>Russell Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hinsdale Orthopaedics</name>
      <address>
        <city>Westmont</city>
        <state>Illinois</state>
        <zip>60559</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Ornelas, PhD</last_name>
      <phone>630-920-2323</phone>
      <email>joe.ornelas@hoasc.com</email>
    </contact>
    <investigator>
      <last_name>Benjamin Domb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital Health System</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Fink</last_name>
      <phone>609-677-7015</phone>
      <email>Benjamin.fink@rothmaninstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Andres Duque</last_name>
      <phone>609-407-6446</phone>
      <email>andres.duque@rothmaninstitute.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fabio Orozco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alvin Ong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zachary Post, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopsital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahava Muskat</last_name>
      <phone>212-606-1510</phone>
      <email>muskata@HSS.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlin Carroll</last_name>
      <phone>646-714-6084</phone>
      <email>carrollk@HSS.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>Geoffrey Westrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seth Jerabek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Orthopaedics</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent Henderson</last_name>
      <phone>919-966-5495</phone>
      <email>brent_henderson@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Del Gaizo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

